• <thead id="vs5lr"><address id="vs5lr"></address></thead>
      <th id="vs5lr"><option id="vs5lr"></option></th>
      1. <code id="vs5lr"><small id="vs5lr"></small></code>
        <code id="vs5lr"><small id="vs5lr"><optgroup id="vs5lr"></optgroup></small></code>
        1. <th id="vs5lr"><option id="vs5lr"></option></th>

          <th id="vs5lr"></th>
          <code id="vs5lr"><nobr id="vs5lr"></nobr></code>

        2. <object id="vs5lr"><video id="vs5lr"><samp id="vs5lr"></samp></video></object>
          <tr id="vs5lr"></tr>

            <thead id="vs5lr"><option id="vs5lr"></option></thead>
            <tr id="vs5lr"></tr>
          1. <big id="vs5lr"></big>
          2. <code id="vs5lr"><small id="vs5lr"><track id="vs5lr"></track></small></code>
            中文版    |    English
              Tel +86-571-88737065   QQ Online
            Company News


            FDA Approves Xpovio

            Synbest 2019-07-05 22:52:45

            Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved oral Xpovio (selinexor), a nuclear export inhibitor, in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody. This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. The ongoing, randomized Phase 3 BOSTON study evaluating selinexor in combination with Velcade® (bortezomib) and low-dose dexamethasone will serve as the confirmatory trial. The FDA’s Accelerated Approval Program was developed to allow for expedited approval of drugs that treat serious conditions and that fill an unmet medical need.  

            Karyopharm expects Xpovio to become commercially available in the U.S. on or before July 10, 2019.  A Marketing Authorization Application for selinexor is also currently under review by the European Medicines Agency.

            “With today’s accelerated approval of Xpovio by the FDA, patients with heavily pretreated multiple myeloma will now have a new therapeutic option to treat their disease,” said Sharon Shacham, PhD, MBA, Founder, President and Chief Scientific Officer of Karyopharm. “Discovering, developing and securing FDA approval for XPOVIO with its novel mechanism of action over the past decade required the dedication of many people, including the patients, caregivers and physicians involved in our clinical trials, along with the many employees at Karyopharm.  We are tremendously grateful for everyone’s contributions to this important milestone, and we look forward to the next stage in our pursuit of improving the lives of patients with cancer.”

            Online services